* Neximmune Inc NEXI.OQ NEXI.O is expected to report
results on November 12.
* Refinitiv's mean analyst estimate for Neximmune Inc is for a
loss of 64 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Neximmune Inc
is $35, about 66.6% above its last closing price
of $11.69.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2021 -0.51 -0.51 -0.54 Missed -5.9
Mar. 31 2021 -0.67 -0.66 -0.71 Missed -7
This summary was machine generated November 10 at 14:02 GMT.
All figures in US dollars unless otherwise stated